International Myeloma Foundation
MYELOMA MINUTE | Up To The Minute News | 9.16.2021
medical research professionals
covid 19 vaccine booster vials on table
Changing the Focus to Overcome the COVID-19 Pandemic
With the increased threat posed by the Delta variant, booster shots are an important new strategy for reducing COVID-19 infections and the variants that come with them, says IMF Chairman Dr. Brian G.M. Durie.
2020BlogButton.png
blood cancer awareness month twitch event banner
Save the Date: #KNOWMYELOMA Variety Show Streaming September 30 on Twitch.tv
The #KNOWMYELOMA Variety Show will stream on Twitch.tv on Thursday, September 30, 2021 at 6 p.m. PT / 9 p.m. ET.  It features performers who have been touched in one way or another by myeloma, including internationally touring comedian Forrest Shaw, “Ologies” podcast host Alie Ward, Dance Theatre of Harlem ballerina Daphne Lee, LA-based writer and mom Jen Curran, IMF Chief Medical Officer Dr. Joseph Mikhael, and more!

The show closes out September’s Blood Cancer Awareness Month (BCAM). Throughout this month, the IMF asks one simple question: “Do You Know Myeloma?” and invites the public to explore the campaign at the link below.
2020LearnMoreButton.png
m power baltimore banner v2
Join the IMF’s Baltimore-Area Campaign to Raise Myeloma Awareness and Improve Outcomes in the African-American Community
To spread the word about the risk and impact of multiple myeloma in the African-American community, the IMF is presenting a free, virtual myeloma workshop on Saturday, September 25, at 10 a.m. ET. In time for September’s Blood Cancer Awareness Month, this workshop is part of the IMF’s initiative in Baltimore and surrounding areas to change the course of multiple myeloma by removing barriers to early diagnosis and treatment for African Americans (for whom myeloma is two times more prevalent than it is in all other races).
register button
RCW roundtable meeting
Register for This October 2nd, Virtual Multiple Myeloma Community Workshop
Do you have questions about a recent myeloma diagnosis? Are you currently undergoing maintenance therapy? Do you want to learn about the latest myeloma clinical trials? Attend the October 2nd Virtual Regional Community Workshop at 10 a.m. ET to learn answers to these questions and more. The panel of myeloma experts for this webinar will include Siddhartha Ganguly, MD, FACP (Houston Methodist); Rafat Abonour, MD (Indiana University Health); and IMF Nurse Leadership Board member Ann McNeill, RN, MSN, APN. IMF Director of Support Groups and Regional Community Workshops Kelly Cox will welcome guests. Attendees will also have time to take part in a Q&A with the experts.
register button
clinical-trials-paper.jpg
Learn More About This Actively Accruing Venetoclax Clinical Trial
The NCT03314181 Trial is an international trial that will enroll approximately 104 patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including an immunomodulatory agent. The overall objective of this study is to evaluate the safety and effectiveness of venetoclax in combination with Darzalex® (daratumumab), and dexamethasone at two dose levels, in comparison to daratumumab, Velcade® (bortezomib), and dexamethasone.
2020LearnMoreButton.png
540x270AmazonSmile.jpg
Choose the IMF as Your Preferred Charity on Amazon Smile
When shopping at Amazon, just type in smile.amazon.com. Choose the International Myeloma Foundation as your designated charity and Amazon will save your choice. This way, Amazon will donate 0.5% of all your purchases to the IMF, each time you shop, at no added cost to you. It’s a win-win! If you still have questions, visit the Amazon Smile FAQ. Or, just follow the steps at the link below.
2020LearnMoreButton.png
490x245NovisGrant.png
Calling All Researchers: Submit Your Grant Applications
The Brian D. Novis Research Grants honor IMF founder Brian Novis, who succumbed to multiple myeloma in July of 1992. The grants are awarded to researchers working in the field of multiple myeloma and related disorders, including smoldering multiple myeloma (SMM), monoclonal gammopathy of undetermined significance (MGUS), and immunoglobulin-derived amyloidosis. The 2022 grants will support senior research projects with $80,000 each and junior research projects with $50,000 each. The deadline to submit the applications is October 1, 2021. 
2020ButtonApplyNow.png
ask doctor durie video image
#ASKDRDURIE | Dr. Durie's Weekly Web Video Series
This Week’s Question:

Is DRd an effective treatment for older, non-transplant eligible myeloma patients?
Watch Now
 
Clinical Trial Fact Sheets

Smart Patients: Join the Conversation

CANOVA Trial (Accruing)

NCT02899052 Trial (Accruing)

NCT03314181 Trial (Accruing)

IKEMA Trial (Fully Accrued)

IMROZ Trial (Fully Accrued)

BOSTON Trial (Fully Accrued)
Upcoming Events & Replays
Register Now
Miracles for Myeloma 2021

Watch the Replay
COVID-19 and Myeloma Webinar

Watch the Replay
Financial Resources Webinar

Click here to see all events
 

We Thank Our Sponsors:

Amgen, Bristol Myers Squibb, Karyopharm Therapeutics, Oncopeptides Inc.,
Sanofi-Genzyme, and Takeda Oncology
We also thank individuals like you for your continued support!
Subscribe Button@2x.jpg
2020ButtonDonateBurg.png
Join the conversation at The International Myeloma Foundation
Facebook Facebook: /Myeloma  |  Twitter Twitter @IMFMyeloma  |  Instagram Instagram @IMFmyeloma

www.myeloma.org
This email was sent by:
The International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607-3421
Connect with the IMF InfoLine
1-800-452-2873
We respect your privacy and your preferences for communications of this nature.
Home  •  Unsubscribe  •  Privacy Policy
View as web page